Sensei Biotherapeutics to Present at H.C. Wainwright Conference on Sept. 8, 2025.

Sensei Biotherapeutics announced that CEO John Celebi will participate in 1x1 investor meetings at the H.C. Wainwright 27th Annual Global Investment Conference on September 8, 2025. An on-demand corporate presentation will be available on September 5, 2025. The company is focused on developing next-generation therapeutics for cancer patients through its TMAb platform.

BOSTON, Sept. 02, 2025 — Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical-stage biotechnology company specializing in the discovery and development of next-generation therapeutics for cancer patients, has announced that its President and Chief Executive Officer, John Celebi, will participate in 1x1 investor meetings at the H.C. Wainwright 27th Annual Global Investment Conference on September 8, 2025.

The company will also provide an on-demand corporate presentation on September 5, 2025, at 7:00 a.m. ET. Investors can access the replay of the webcast in the Investors section of the Sensei website for approximately 90 days following the event.

Sensei Biotherapeutics is focused on developing conditionally active therapeutics through its TMAb™ (Tumor Microenvironment Activated biologics) platform. This platform aims to disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment, thereby unleashing T cells against tumors. The company’s lead product candidate is solnerstotug, a conditionally active antibody designed to block the V-domain Ig suppressor of T cell activation (VISTA) checkpoint selectively within the low pH tumor microenvironment.

For more information, please visit www.senseibio.com or follow the company on X @SenseiBio and LinkedIn.

References:
[1] https://www.globenewswire.com/news-release/2025/09/03/3143511/0/en/Sensei-Biotherapeutics-to-Participate-in-the-H-C-Wainwright-27th-Annual-Global-Investment-Conference.html